Ichnos Glenmark Innovation, Inc.

Ichnos Glenmark Innovation will present updated Phase 1 clinical data for ISB 2001 in multiple myeloma at the ASH Annual Meeting. ISB 2001 is a first-in-class trispecific T-cell engager targeting CD38